The plasma fractionation market is witnessing remarkable growth driven by the latest technological advancements. Innovations in fractionation techniques, such as chromatography and ultrafiltration, enhance plasma-derived product purity and yield. Automation and digitization streamline manufacturing processes, ensuring efficiency and scalability. Furthermore, advancements in protein engineering enable the development of novel therapeutics with enhanced efficacy and safety profiles. With the increasing prevalence of chronic diseases and growing demand for plasma-derived therapies, the market is poised for substantial expansion. This convergence of technology and healthcare underscores a promising future for plasma fractionation.
The Global Plasma Fractionation Market size was valued at USD 29,259.96 million in 2023, is expected to reach USD 48,425.11 million by 2031, at a CAGR of 6.5% during the forecast period 2024 to 2031.
Below are the Top Five Plasma Fractionation Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
CSL Plasma
|
As a division of CSL Behring, CSL Plasma is a key player in the plasma fractionation market. It operates plasma collection centers globally, supplying raw materials for the production of life-saving therapies. With a focus on innovation and efficiency, CSL Plasma contributes significantly to meeting the increasing demand for plasma-derived products worldwide. Its commitment to quality and safety ensures the delivery of high-quality plasma for fractionation, supporting the development of vital therapies for patients in need.
|
|
America, Europe
|
In May 2021, CSL Pharma and The Colorado Cross-Disability Coalition formed an agreement to expand opportunities for people with disabilities to donate plasma. This will help the company enhance its ability to provide plasma to treat individuals suffering from serious diseases.
|
|
2.
|
Grifols, S.A.
|
Grifols is a leading global healthcare company specializing in plasma-derived therapies. With a vertically integrated business model, it engages in plasma collection, processing, and fractionation, as well as research and development of new treatments. Grifols' extensive network of plasma centers enables it to secure a stable supply of plasma, which is essential for producing a diverse range of therapeutic products. Through strategic investments and partnerships, Grifols continues to expand its presence in the plasma fractionation market, aiming to address unmet medical needs and improve patient outcomes worldwide.
|
|
Middle East, America, Europe, Asia-Pacific
|
In May 2021, Grifols, S.A. announced a collaboration with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR. This will help the company to expand in basic and applied research related to diseases such as Alzheimer’s, among others.
|
|
3.
|
Octapharma AG
|
Octapharma is a family-owned company dedicated to providing high-quality plasma-derived therapies globally. With a focus on research and development, it offers a broad portfolio of products for treating various medical conditions, including immunodeficiencies, bleeding disorders, and autoimmune diseases. Octapharma's state-of-the-art fractionation facilities ensure the efficient extraction of therapeutic proteins from plasma, maintaining stringent quality standards throughout the manufacturing process. Through ongoing innovation and investment in technology, Octapharma remains at the forefront of the plasma fractionation market, striving to enhance patient care and quality of life.
|
|
Middle East and Africa, Europe, America, and Asia-Pacific
|
In January 2021, Octapharma AG signed a global agreement with Akron Biotech to produce virally inactivated human AB serum derived from Octaplas for the cell therapy market. This will help the company to support research and development requirements with a view to eventual commercialization.
|
|
4.
|
Kedrion S.p.A
|
Kedrion is an Italian biopharmaceutical company specializing in the development and production of plasma-derived therapies. With a strong focus on research and innovation, Kedrion offers a diverse portfolio of products for the treatment of rare and serious diseases, including hemophilia, immune deficiencies, and neurological disorders. Its advanced fractionation facilities enable the extraction of essential plasma proteins, ensuring the production of safe and effective therapies. Kedrion's commitment to scientific excellence and patient-centric approach positions it as a trusted leader in the global plasma fractionation market, dedicated to improving the lives of patients worldwide.
|
|
North America, Europe, Middle East and Africa, and Asia
|
In September 2021, Kedrion S.p.A collaboration announced that the first patient had been recruited to the phase ½ clinical trial of an anti-SARS- CoV-2 plasma-derived immunoglobulin product as a potential treatment for coronavirus in Israel. This development helped the company to increase its income and grab the attention of the consumers.
|
|
5.
|
Takeda Pharmaceutical Company Limited
|
Takeda is a global biopharmaceutical company with a significant presence in the plasma fractionation market. Through its subsidiary, Takeda Plasma Solutions, the company collects and processes plasma to manufacture a range of therapeutic products. Takeda's extensive research and development efforts focus on advancing treatments for rare diseases and disorders, leveraging its expertise in plasma fractionation technology. By investing in innovation and strategic partnerships, Takeda aims to address unmet medical needs and enhance access to life-saving therapies for patients around the world.
|
|
Middle East, Europe, Asia-Pacific, America
|
In April 2021, Takeda Pharmaceutical Company Limited announced that the International Society had awarded it for Pharmaceutical Engineering (ISPE) for the 2021 Facility of the Year Awards (FOYA). This recognition will help the company build trust among its partner for higher authenticity as the company is constantly investing in state-of-the-art facilities applying best-in-class processes and digital standards.
|
Conclusion
The plasma fractionation market exhibits promising growth prospects, fueled by increasing demand for plasma-derived therapeutics, technological advancements, and the rising prevalence of chronic diseases worldwide. The expanding geriatric population and growing awareness regarding the benefits of plasma-derived products further bolster market expansion. In addition, supportive government initiatives and investments in healthcare infrastructure contribute to the market's upward trajectory. As the pharmaceutical industry continues to innovate and address unmet medical needs, the plasma fractionation sector stands poised for substantial growth, offering significant opportunities for stakeholders to capitalize on emerging trends and advancements.
